Alimera Sciences

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Alimera Sciences excels in Q1 2024, eyes revenue growth and market expansion

Alimera Sciences' Q1 2024 performance reflects robust revenue growth, profitability improvements, and strategic initiatives to drive product awareness and clinical advancements.
While facing challenges in margin stabilization and cost management, the company is well-positioned to capitalize on opportunities like indication expansion and sales optimization.
Overall, Alimera Sciences' strong financial performance, focus on innovation, and market expansion efforts position it for continued growth and success in the ophthalmic pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alimera Sciences is a pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. The company is passionate about protecting the retina and developing innovative treatments to preserve vision.

Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME) NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME)

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately.

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies.

Alimera Appoints Maggie A. Pax to Its Board of Directors

Alimera Sciences, Inc. (ALIM) Q3 2023 Earnings Call Transcript

Alimera Sciences (ALIM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.75 per share a year ago.

Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates

ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Alimera Sciences Reports Third Quarter 2023 Results

ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg and YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg will be featured in five presentations during the Retina Society's 56th Annual Scientific Meeting being held in New York City from October 11-14, 2023.

Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress

ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer (“COO”), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations.

Alimera Sciences Appoints Jason Werner as Chief Operating Officer

Alimera Sciences, Inc. (NASDAQ:ALIM ) Q2 2023 Earnings Conference Call August 10, 2023 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President, CEO & Director Russell Skibsted - SVP & CFO Conference Call Participants Alexander Nowak - Craig-Hallum James Molloy - Alliance Global Partners Yi Chen - H.C. Wainwright & Co. Operator Ladies and gentlemen, thank you for standing by.

Alimera Sciences, Inc. (ALIM) Q2 2023 Earnings Call Transcript

Alimera Sciences (ALIM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.45 per share a year ago.

Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates

ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2023.

Alimera Sciences Reports Second Quarter 2023 Results

ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report second quarter financial results on August 10, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.

Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Alimera Sciences (ALIM) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Alimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced Momentum

Here is how Alimera Sciences (ALIM) and Haemonetics (HAE) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?

Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.

Alimera (ALIM) Completes Enrollment in Eye Disease Study

Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Alimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain Stock

Alimera Sciences  ALIM announced acquiring additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq from EyePoint Pharmaceuticals, Inc. Yutiq is indicated to treat chronic non-infectious uveitis affecting the posterior segment of the eye.

Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq

Alimera Sciences (NASDAQ: ALIM ) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (NASDAQ: EYPT ). That agreement has Alimera Sciences acquiring additional commercialization rights for YUTIQ from EyePoint Pharmaceuticals.

Why Is Alimera Sciences (ALIM) Stock Up 21% Today?

ATLANTA, May 18, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced its acquisition of additional commercialization rights for YUTIQ (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals, Inc. (EyePoint). A live conference call will be hosted today at 8:30 a.m. ET to provide a corporate update. Please refer to the information in the paragraphs below for conference call dial-in information and webcast registration.

Alimera Acquires U.S. Commercial Rights to YUTIQ®

ATLANTA, May 17, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will host its rescheduled corporate update conference call to review first quarter financial results and provide an update on corporate developments on Thursday, May 18, 2023, at 8:30am ET. Following management's formal remarks there will be a question-and-answer session.

Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET

Alimera Sciences (ALIM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.85 per share a year ago.

Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates

ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2023.

Alimera Sciences Reports First Quarter 2023 Results

ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 15, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.

News for Alimera Sciences Stock (ALIM)